Bristol-Myers Squibb (NY: BMY)
49.46 USD  +0.35 (+0.71%)
Official Closing Price  /  Updated: 4:15 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(BMY) Community Analysis from
April 17, 2014
(Jutia Group, 4/14/14)
[Business Wire] - Bristol-Myers Squibb Company...(read more)
(Jutia Group, 4/7/14)
[Business Wire] - Bristol-Myers Squibb Company announced today that they have submitted new drug applications...(read more)
(Samurai Trader, 10/28/13)
BMY was one of few breakouts today, and is interesting in a couple of things I noticed here. First off, this is a cup and handle pattern, but the handle is rising rather than sloping down, which (if I recall correctly) is...(read more)
Bristol-Myers Squibb Company (BMY) Company Overview

This article is about Bristol-Myers Squibb. For the article on the company with ticker BMS, see Bemis Company (BMS).

Bristol-Myers Squibb (NYSE: BMY) is one of the world's largest pharmaceutical companies by total sales. Bristol-Myers Squibb offers treatments for cardiovascular disease, HIV/AIDS, hepatitis, cancer, and rheumatoid arthritis. Cancer treatments in particular represent a major portion of the company's long-term growth potential and have historically been a strong suit of Bristol-Myers Squibb. The company's top three blockbuster drugs (annual sales >$1 billion) are blood thinner Plavix, Abilify for schizophrenia, and Reyataz for HIV. In FY 2010, BMY generated revenues of $19.5B and net earnings of $3.1B.[1]

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here